23 Feb RootPath
Xi Chen, Ph.D., CEO
RootPath is a Massachusetts based preclinical-stage biotechnology company pioneering synthetic immunology and its therapeutic applications. With our Synthetic Immunology platform, we are the only group in the world that can ‘Read’, ‘Write’, and ‘Mine’ the immune system fast and inexpensively enough to enable personalized discovery of therapeutic TCRs. Our lead program is a personalized cell therapy for solid tumors. Future opportunities include infectious and autoimmune diseases. RootPath was launched in 2017 by Nest.bio Ventures and has raised $18M in seed and Series A financing.